SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob^-/- mice.

Fasting biomarkers at termination Cardiac biomarker There was a trend for N-terminal pro b-type natriuretic peptide to be lower in the treated ob/ob −/− group compared to the untreated, although it did not reach statistical significance (p = 0.0891) (Table 3 ).

also in 111,027 other papers

The empagliflozin treated animals experienced a highly significant reduction in HbA1c compared to untreated animals both at 5 and 10 weeks treatment (Fig. 3 a).

also in 132,142 other papers